

## Benlysta IV

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	
Physician Office Telephone:	
Referring Provider Info: 🗆 Same as Re	equesting Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: 🗖 Same as Ro	eferring Provider 🗆 Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:
	t to dosing limits in accordance with FDA-approved labeling, pendia, and/or evidence-based practice guidelines.
Required Demographic Information:	
Patient Weight:	kg
Patient Height:	ст

	where will this drug be administered?  Where will this drug be administered?  □ Ambulatory surgical, skip to Clinical Questions  □ Off-campus Outpatient Hospital  □ Physician office, skip to Clinical Questions	☐ Home infusion, <i>skip to Clinical Questions</i> ☐ On-campus Outpatient Hospital☐ Pharmacy, <i>skip to Clinical Questions</i>	
B.	<ul> <li>How many doses of the requested product has the patient received?</li> <li>□ 2 or more doses → This is a continuation of an existing treatment.</li> <li>□ 0 to 1 dose → This is a new request OR the patient has received only1 dose. skip to Clinical Criteria Questions</li> </ul>		
C.	Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre-medications or slowing of the infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? <i>ACTION REQUIRED: If Yes, Attach supporting clinical documentation.</i> $\square$ Yes, <i>skip to Clinical Criteria Questions</i> $\square$ No		
D.	. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?  **ACTION REQUIRED: If Yes, Attach supporting clinical documentation.**  □ Yes, skip to Clinical Criteria Questions □ No		
E.	Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? <i>ACTION REQUIRED: If Yes, Attach supporting clinical documentation.</i> ☐ Yes, <i>skip to Clinical Criteria Questions</i> ☐ No		
F.	Does the patient have significant behavioral issues and/or safety of the infusion therapy AND the patient does not ha <i>Attach supporting clinical documentation.</i> Yes, <i>skip</i>	ve access to a caregiver? ACTION REQUIRED: If Yes,	
G.	Are alternative infusion sites (pharmacy, physician office, the patient's home? ACTION REQUIRED: If Yes, Atta	ambulatory care, etc) not within a reasonable distance from <i>ch supporting documentation</i> . $\square$ Yes $\square$ No	

Cli	nical Criteria Questions:		
1.	What is the patient's diagnosis?  ☐ Active systemic lupus erythematosus (SLE) ☐ Active lupus nephritis ☐ Other		
2.	What is the ICD-10 code?		
3.			
4.	Is the patient currently receiving treatment with the requested medication? $\square$ Yes $\square$ No If No, skip to #6		
5.	. Has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition?   Yes  No No further questions		
6.	Does the patient have severe active central nervous system (CNS) lupus [including seizures that are attributed to CNS lupus, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis requiring therapeutic intervention within 60 days before initiation of belimumab (Benlysta)]?		
Con	nplete the following section based on the patient's diagnosis, if applicable.		
	rtion A: Systemic lupus erythematosus (SLE)  Prior to initiating therapy, is the patient positive for autoantibodies relevant to systemic lupus erythematosus?  Yes No Unknown		
8.	Is the patient currently receiving a stable standard treatment regimen for systemic lupus erythematosus (SLE) with any of the following (alone or in combination)?  ☐ Glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone) ☐ Antimalarials (e.g., hydroxychloroquine) ☐ Immunosuppressives (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide) ☐ None of the above		
	tion B: Active lupus nephritis		
9.	Prior to initiating therapy, is the patient positive for autoantibodies relevant to systemic lupus erythematosus?  Yes No Unknown		
10.	Is the patient currently receiving a stable standard induction and maintenance treatment for lupus nephritis (e.g., cyclophosphamide, mycophenolate mofetil, azathioprine, glucocorticoids)?    Yes   No		
	ttest that this information is accurate and true, and that documentation supporting this formation is available for review if requested by CVS Caremark or the benefit plan sponsor.		
<b>X</b> _			
Pre	escriber or Authorized Signature Date (mm/dd/yy)		

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. SOC Benlysta SGM – 03/2021.

CVS Caremark Specialty Pharmacy

• 2211 Sanders Road NBT-6

• Northbrook, IL 60062

Phone: 1-888-877-0518

• Fax: 1-855-330-1720

• www.caremark.com